Peripheral & central neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Generalised anxiety disorder (GAD) in adults.
150-600 mg/day given in 2 or 3 divided doses. Neuropathic pain Initially 150 mg/day in 2 or 3 divided doses, may be increased to 300 mg/day after an interval of 3-7 days. Max: 600 mg/day after an additional 7-day interval. Epilepsy Initially 150 mg/day in 2 or 3 divided doses, may be increased to 300 mg/day after 1 wk. Max: 600 mg/day after an additional wk. GAD Initially 150 mg/day, may be increased to 300 mg/day after 1 wk. Following an additional wk, dose may be increased to 450 mg/day. Max: 600 mg/day after an additional wk. Renal impairment CrCl ≥60 mL/min Initially 150 mg/day bid or tid, max: 600 mg/day, ≥30-<60 mL/min Initially 75 mg/day bid or tid, max: 300 mg/day; ≥15-<30 mL/min Initially 25-50 mg/day once daily or bid, max: 150 mg/day, <15 mL/min Initially 25 mg/day once daily, max: 75 mg/day. Supplementary dosage following haemodialysis: Initially 25 mg as a single dose, max: 100 mg/day.
Diabetic patients. Discontinue immediately if symptoms of angioedema eg, facial, perioral or upper airway swelling occur. Dizziness, somnolence, loss of consciousness, confusion & mental impairment. Vision-related effects. Renal failure. W/drawal symptoms. CHF in elderly CV compromised patients. Increased incidence of AR in treatment of central neuropathic pain due to spinal cord injury & additive effect w/ concomitant medicinal products (eg, anti-spasticity agents). Suicidal ideation & behaviour. Reduced lower GIT function. History of substance abuse & monitor for symptoms of pregabalin misuse, abuse or dependence. May precipitate encephalopathy. May have minor or moderate influence on the ability to drive & use machines. Women of childbearing potential/contraception in males & females. Pregnancy & lactation.
Sign Out
